$27.81−1.07 (−3.71%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Immunocore Holdings (IMCR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
2 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~82.0%/yr (FY21→FY25), net margin −8.9%. Worth your attention in FY25: Share count (+18.5%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲29.0%
400.0
FY21→FY25CAGR +82.0%/yr
Net income ($M)▲30.5%
−35.5
one-off year: see footnoteCAGR —
Free cash flow ($M)—
−15.1
FY21→FY25CAGR —
Diluted EPS▲30.4%
−0.71
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+18.5%
42.5mn → 50.3mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$4.3M
−16.1% YoY in FY25 · 1.1% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -8.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 429,304.0 | 400,016.0 | 310,202.0 | 249,428.0 | 174,361.0 | 36,484.0 | ▲29.0% | +82.0% |
Cost of revenue | 4,901.0 | 5,087.0 | 2,731.0 | 1,037.0 | 1,089.0 | 0.0 | ▲86.3% | +67.2% (22→25) |
Gross profit | 424,403.0 | 394,929.0 | 307,471.0 | 248,391.0 | 173,272.0 | —A | ▲28.4% | +31.6% |
Research & development | 288,582.0 | 274,869.0 | 222,151.0 | 163,545.0 | 101,921.0 | 100,248.0 | ▲23.7% | +28.7% |
Selling, general & admin | 164,837.0 | 165,413.0 | 155,781.0 | 144,495.0 | 123,059.0 | 110,823.0 | ▲6.2% | +10.5% |
Total operating expenses | 453,419.0 | 440,282.0 | 377,932.0 | 308,040.0 | 224,980.0 | 211,071.0 | ▲16.5% | +20.2% |
Operating incomefeeds ROC rank | −29,016.0 | −45,353.0 | −70,461.0 | −59,649.0 | −51,708.0 | −174,587.0 | ▲35.6% | — |
Other income, net | 11,911.0 | 26,253.0 | 17,524.0 | −1,241.0 | 10,825.0 | −5,292.0 | — | — |
Pretax income | −17,105.0 | −19,100.0 | −52,937.0 | −60,890.0 | −40,883.0 | −179,879.0 | ▲63.9% | — |
Income tax | 15,014.0 | 16,414.0 | −1,850.0 | −5,603.0 | 11,660.0 | 150.0 | — | +223.4% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −32,119.0 | −35,514.0 | −51,087.0 | −55,287.0 | −52,543.0 | −180,029.0 | ▲30.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.66 | −0.71 | −1.02 | −1.13 | −1.15 | −4.24 | ▲30.4% | — |
Diluted shares (mn) | 51.56 | 50.35 | 49.99 | 48.89 | 45.71 | 42.49 | ▲0.7% | +4.3% |
| Margins | ||||||||
Gross margin98th pct in Healthcare | 98.9% | 98.7% | 99.1% | 99.6% | 99.4% | —A | ▼0.4pp | −0.6pp |
Operating margin | −6.8% | −11.3% | −22.7% | −23.9% | −29.7% | −478.5% | ▲11.4pp | +467.2pp |
Net margin28th pct in Healthcare | −7.5% | −8.9% | −16.5% | −22.2% | −30.1% | −493.4% | ▲7.6pp | +484.6pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −29% vs a −0% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was 9% vs a −0% norm for this window, likely a one-time item; see the filing.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Immunocore Holdings' revenue last fiscal year?
Immunocore Holdings reported revenue of $400.0M in fiscal 2025, up 29.0% from fiscal 2024.
What was Immunocore Holdings' net income?
Immunocore Holdings reported net income of −$35.5M in fiscal 2025, a net margin of −8.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

